What Happened: CVS said it would buy Oak Street in an all-cash deal valued at $39 per share, representing an enterprise value of about $10.6 billion. This per-share price represents a 15.8% premium over the target company’s closing price of $33.68 on Tuesday.
See Also: Best Healthcare Stocks
Incidentally, reacting to a Wall Street report of a potential deal, Oak Street shares ended Tuesday’s session 29.74% higher. At one point in the session, the stock hit an intraday high of $34.63.
The purchase price is about 50.2% higher than Oak Street’s closing price of $25.96 on Monday — the session before the rumor broke out.
“Combining Oak Street Health’s platform with CVS Health’s unmatched reach will create the premier value-based primary care solution,” said CVS Health President and CEO Karen Lynch.
The deal is expected to close in 2023. By 2026, CVS expects Oak Street will likely contribute $2 billion in adjusted EBITDA and synergy potential of $500 million over time.
Arbitrage Opportunity: StoryTrading founder Ben Rabizadeh said there is an arbitrage opportunity available, given Oak Street is trading under $35.
He also flagged Cano Health Inc. (NYSE:CANO), Talkspace Inc. (NASDAQ:TALK) and DarioHealth Inc. (NASDAQ:DRIO) as sympathy play.
According to Benzinga Pro data:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
